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esponsibility of Xi’Abstract A rapid, sensitive and selective pseudoMRM (pMRM)-based method for the determination of
solutol HS15 (SHS15) in rat plasma was developed using liquid chromatography/tandem mass spectro-
metry (LC–MS/MS). The most abundant ions corresponding to SHS15 free polyethyleneglycol (PEG)
oligomers at m/z 481, 525, 569, 613, 657, 701, 745, 789, 833, 877, 921 and 965 were selected for pMRM
in electrospray mode of ionization. Purity of the lipophilic and hydrophilic components of SHS15 was
estimated using evaporative light scattering detector (ELSD). Plasma concentrations of SHS15 were
measured after oral administration at 2.50 g/kg dose and intravenous administration at 1.00 g/kg dose in
male Sprague Dawley rats. SHS15 has poor oral bioavailability of 13.74% in rats. Differences in
pharmacokinetics of oligomers were studied. A novel proposal was conveyed to the scientiﬁc community,
where formulation excipient could be analyzed as a qualiﬁer in the analysis of new chemical entities
(NCEs) to address the spiky plasma concentration proﬁles.
& 2014 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
In the early stages of drug discovery, pharmacokinetic, drug
metabolism and disposition studies will be conducted in rodentssity. Production and hosting by Else
2
ratory (Biology Division), GVK
esh 500076, India.
ail.com (V.V. Bhaskar).
an Jiaotong University.as they are relatively inexpensive and can be easily acquired and
handled [1]. In a typical pharmacokinetic study, new chemical
entities (NCEs) are administered to rats via intravenous and oral
routes. Serial blood samples are collected and analyzed by liquid
chromatography/tandem mass spectrometry (LC–MS/MS). Few
NCEs have spiky plasma concentration proﬁles and various
reasons for such proﬁles could be due to enterohepatic circulation,
or discrepancies in sample collection/sample processing. Spiky
proﬁles in elimination phase will lead to inaccurate quantiﬁcation
of pharmacokinetic parameters. Extensive studies should bevier B.V. All rights reserved.
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compounds. Drugs that undergo enterohepatic cycling to a
signiﬁcant extent include colchicine, phenytoin, leﬂunomide and
tetracycline antibiotics [2]. As formulation excipients have ﬁxed
plasma concentration proﬁles irrespective of the NCE dosed,
monitoring the plasma concentration levels of excipient helps to
take a decision on the spiky plasma concentration proﬁles of
NCEs. A thoroughly developed and validated bioanalytical
method is required to ﬁx the plasma concentration proﬁle and
understand the pharmacokinetic disposition of formulation exci-
pient studied. Integrity of results from pharmacokinetic studies can
be cross veriﬁed if formulation excipients that have ﬁxed plasma
concentration proﬁle/pharmacokinetic parameters are monitored
along with the test compound studied. Solutol HS15 (SHS15) is
the excipient of choice for chemotherapy drugs as severe toxicity
concerns were raised with the use of cremophor EL as a
formulation excipient [3]. SHS15 has better solubilizing capacity
for a wide variety of compounds [4]. This excipient has been
proved to be safe in preclinical species and recommended for
preclincal pharmacokinetic studies [5]. SHS15 is a nonionic
emulsifying agent obtained by reacting 15 mol of ethylene oxide
with 1 mol of 12-hydroxystearic acid. SHS15 consists of about
70% of mono- and diesters of 12 hydroxystearic acid (lipophilic
part) and 30% of free polyethyleneglycol (hydrophilic part) [6]. To
our knowledge, there has been no LC–MS/MS method reported
for the quantitative estimation of SHS15. A gel permeation
chromatography method with selective wavelength detector was
reported for the analysis of SHS15 [7]. But, the objective of this
method was to check the reversal of multi-drug resistance for
various fractions of SHS15 collected, instead of quantitative
application. In the present work, an attempt was made to develop
and validate a bioanalytical method for the quantitative estimation
of SHS15 using LC–MS/MS and present the plasma concentration
proﬁle/pharmacokinetic parameters in male Sprague Dawley rats.
Pharmacokinetic parameters for SHS15 and differences in phar-
macokinetics of its oligomers were established.2. Experimental
2.1. Materials
SHS15, dimethyl sulfoxide (DMSO) and telmisartan (internal
standard) were procured from Sigma-Aldrich Co. (St. Louis,
MO, USA). Acetonitrile, water and acetone (HPLC grade) were
procured from Merck specialities Pvt. Ltd. (Mumbai, India).
Formic acid (90% puriﬁed) was procured from Merck specialities
Pvt. Ltd. (Mumbai, India). Sprague Dawley rats were obtained
from Bioneeds Ltd. (Bangalore, India). Vacutainers (lithium heparin
as anticoagulant) were sourced from BD (Franklin lakes, USA).
2.2. Estimation of hydrophilic and lipophilic components
of SHS15
Percentage of hydrophilic and lipophilic components of SHS15
was estimated by using an HPLC system equipped with an
evaporative light scattering detector (ELSD) (Agilent, Santaclara,
USA). The HPLC system consisted of an Agilent 1200 RRLC
(Agilent, Santaclara, USA). The stationary phase was XBridge C18
(250 mm 3.0 mm, 5 mm) (Waters, Milford, USA). The mobile
phase consisted of 0.1% formic acid in water as aqueous
component (A) and 100% acetonitrile as organic modiﬁer (B).A generic gradient LC method (time (min)/%B¼0.01/2, 25.00/50,
45.00/95, 50.00/95, 55.00/2, 60.00/2) with a run time of 60 min
and a ﬂow rate of 0.5 mL/min was developed for the purity
analysis of SHS15. The column and autosampler were maintained
at 40 and 4 1C, respectively. The ELSD was operated with typical
settings as follows: evaporation temperature, 75 1C; nebulizer
temperature, 80 1C; and gas, 1.65 standard liter per minute (SLM).
2.3. Plasma stability determination of SHS15
Master stock solution (40 mg/mL) of SHS15 was prepared in DMSO.
10 mL of the master stock was spiked in 390 mL of plasma to obtain a
ﬁnal concentration of 1 mg/mL. Samples were incubated for 1 h
at 37 1C in rat plasma. Samples were incubated on thermomixer
(Eppendorf, Hamburg, Germany) at vortex speed of 600 rpm.
Reaction was terminated at different time intervals (5, 10, 20, 40,
60 min) by precipitating 50 mL of incubation mixture with 200 mL
of acetonitrile containing telmisartan as an internal standard (IS).
0 min control samples were prepared in heat inactivated plasma
(heated at 70 1C for 5 min) and 50 mL of the sample was
precipitated with 200 mL of acetonitrile containing telmisartan as
the IS. Samples were vortex mixed for 10 min at 1200 rpm and
centrifuged at 3350g for 10 min. 50 mL of supernatant was
transferred to a fresh analysis plate and diluted with 450 mL of
methanol:water (1:1). Aliquots of 10 mL were injected for LC–MS/
MS analysis.
2.4. Preparation of calibration standards and quality control
(QC) samples
Master stock solutions of SHS15 (40 mg/mL) and telmisartan (1 mg/
mL) were prepared in DMSO. Working standard solutions of SHS15
were prepared by serial diluting master stock with acetonitrile:
DMSO:water (2:2:1). Working standard solutions were prepared at
25-fold higher concentration than plasma calibration standards and
QC samples. A total of nine plasma calibration standards (0.40, 0.80,
4.01, 20.04, 57.26, 104.12, 148.74, 167.31 and 185.90 mg/mL) and
quality control samples (1.64, 117.12 and 156.16 mg/mL) of SHS15
(free PEG oligomers) were prepared by spiking 2 mL of the working
standard solutions into 48 mL of blank rat plasma. The working
solution for internal standard (100 ng/mL) was prepared by diluting
an aliquot of master stock solution with acetonitrile. Master and
working stock solutions were stored at 4 1C when not in use.
2.5. Sample preparation
A 50 mL aliquot of plasma (blank control plasma, plasma samples
from rats dosed with SHS15, blank plasma spiked with calibration
standards and QC samples) was pipetted into a 96 well poly-
propylene plate and extracted with 200 mL of acetonitrile contain-
ing internal standard. Samples were vortex mixed for 10 min at
1200 rpm and centrifuged at 3350g for 10 min at 4 1C. 50 mL of
supernatant was pipette transferred into a fresh analysis plate and
diluted with 450 mL of methanol:water (1:1). 10 mL aliquots were
injected for LC–MS/MS analysis.
2.6. LC–MS/MS analysis
All mass spectrometric estimations were performed on a Sciex 3200
QTrap triple quadrupole instrument with turboionspray (AB Sciex,
Toronto, Canada) using C18 column (50 mm 4.6 mm, 2.5 mm)
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LC20AD UFLC pumps and a SIL HTC autosampler (Shimadzu,
Kyoto, Japan). The mobile phase consisted of 0.1% formic acid in
water as aqueous component (A) and 100% acetone as organic
modiﬁer (B). A generic gradient LC method (time (min)/%
B¼0.01/5, 2.50/95, 3.50/95, 3.60/5, 5.00/5) with a short run time
of 5 min and a ﬂow rate of 1.00 mL/min was developed for the
analysis of SHS15 in plasma samples. The column and auto-
sampler were maintained at 40 and 4 1C, respectively. The
turboionspray source was operated with typical settings as follows:
ionization mode, positive; curtain gas, 20 psi; nebulizer gas (GS1),
50 psi; heater gas (GS2), 50 psi; ionspray voltage, 5500 V;
temperature, 550 1C. The mass spectrometer was set up to perform
in MS mode and to run in pseudoMRM mode. The molecular ions
of SHS15 and telmisartan were formed using the declustering
potentials of 140 and 40 V, respectively. In pseudoMRM mode the
most abundant and informative molecular ions of free PEG
oligomers were selected at m/z 481.5 (Oligomer 1), 521.5
(Oligomer 2), 569.5 (Oligomer 3), 613.5 (Oligomer 4), 657.5
(Oligomer 5), 701.5 (Oligomer 6), 745.5 (Oligomer 7), 789.5
(Oligomer 8), 833.5 (Oligomer 9), 877.5 (Oligomer 10), 921.5
(Oligomer 11), 965.5 (Oligomer 12) with medium CAD gas
setting at a collision energy of 5 V. Molecular ion (m/z, 515.30)
of telmisartan was fragmented to m/z 276.10 at collision energy of
65 V with medium CAD gas setting. High-purity nitrogen (99.99%
pure) was used as nebulizer, curtain, heater and CAD gas. Peak
areas for all components were automatically integrated using
Analyst software version 1.5.
2.7. Method validation
Method validation was performed on the total SHS15 (free PEG
oligomers), instead of each oligomer. Three precision and accuracy
batches, consisting of calibration standards (0.40, 0.80, 4.01, 20.04,
57.26, 104.12, 148.74, 167.31, and 185.90 mg/mL), were analyzed on
three different days to complete the method validation. In each batch,
QC samples at 1.64, 117.12, 156.16 mg/mL were assayed in sets of six
replicates to evaluate the intra- and inter-day precision and accuracy.
Relative error (RE) and coeffecient of variation (CV) were served as the
measure of accuracy and precision, respectively. The selectivity was
evaluated by analyzing blank plasma samples obtained from different
animals. Extraction efﬁciency of SHS15 was determined by comparing
peak areas of analyte spiked before extraction into six different lots of
plasma with those of the analyte post-spiked into plasma extracts. Matrix
effect was evaluated from matrix factor values. Matrix factor was
calculated by dividing mean peak areas of analyte post spiked into
plasma extracts with those of analyte spiked into neat solutions at three
QC levels. To assess post-preparative stability, six replicates of QC
samples at each of the low, mid and high concentrations were processed
and stored under autosampler conditions for 24 h before analysis. To
assess bench-top stability, six replicates of QC samples at each of the
low, mid and high concentrations were kept at room temperature for 8 h
before analysis. Freeze-thaw stability was assessed at three QC levels for
three freeze-thaw cycles. To assess long-term stability, six replicates of
QC samples at each of the low, mid and high concentrations were kept
at 80 1C for 60 days before analysis.
2.8. Application
SHS15 was administered intravenously (lateral tail vein) at 1.0 g/kg
dose and orally (oral gavage needle) at 2.5 g/kg dose to fastedmale Sprague Dawley rats. The volume of administered dose was
5 mL/kg. The composition of dosing vehicle used for intravenous
route of administration was ethanol/SHS15/water (10:20:70, v/v/v)
[8,9]. The composition of dosing vehicle used for oral route of
administration was ethanol/SHS15/water (10:50:40, v/v/v) [8,9].
Serial blood samples were collected into vacutainers containing
lithium heparin (anticoagulant) at 0.08, 0.25, 0.50, 1, 2, 4, 8 and
24 h [10] after intravenous administration and 0.25, 0.50, 1, 2, 4, 8
and 24 h [10] after oral administration. At each time point, 200 mL
of blood was collected into vacutainers. Blood samples were
collected using the retro orbital puncture method. Plasma was
isolated by centrifugation at 10,000 rpm for 10 min and stored
frozen at 80 1C until assay. Pharmacokinetic parameters including
elimination rate constant (Kel), half life (T1/2), extrapolated drug
concentration (C0), AUC0-last, AUC0-inf, AUC%Extrapolated, volume of
distribution (Vd), clearance (Cl), Tmax, Cmax, MRTlast and absolute
bioavailability (%F) were calculated using phoenix winnonlin
software (v6.3). Absolute bioavailability was calculated using
AUC0-inf values as AUC%Extrapolated was less than 20%.3. Results and discussion
3.1. Percentage of hydrophilic and lipophilic components
of SHS15
Hydrophilic and lipophilic components of SHS15 have very weak
ultraviolet (UV) absorbance and need to be separated by gradient
elution chromatography. This precludes their detection by UV and
refractive index (RI). RI and low wavelength UV detection are
highly subject to baseline drifts with gradients and have limited
solvent selection. Conversely, ELSD allows direct detection of
components of SHS15 without derivatisation and is compatible
with gradient elution chromatography. Longer gradient program
with maximum % acetonitrile ramped to 95% has achieved good
separation between hydrophilic and lipophilic components of
SHS15 (Fig. 1). Ramping to lower percentages of acetonitrile in
the gradient program (75–80%) did not achieve complete elution
of lipophilic component of SHS15. Percentage of each oligomer
was estimated by area normalization method (percentage of each
oligomer was calculated by summing up peak area of all the
components to 100%). Percentage of oligomers 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 11 and 12 was 0.41%, 1.044%, 1.903%, 4.037%, 5.181%,
5.246%, 5.092%, 5.087%, 4.034%, 2.415%, 1.542% and 0.665%,
respectively. Purity of lipophilic and hydrophilic components was
found to be 63.344% and 36.656%, respectively. Estimated purity
was in match with the supplier’s speciﬁcations [6].3.2. Plasma stability of SHS15
Lipophilic component of SHS15 was found very fast hydrolyzing
(ester hydrolysis) in rat plasma with o1% remaining at 60 min
(Fig. 2A). This could be due to esterases present at higher levels in
rat species causing hydrolysis of lipophilic component of SHS15.
Similarly hydrophilic component was found stable in 60 min
incubation period. Insource fragment (m/z, 309.20) (Fig. 2B)
was analyzed in pseudoMRM mode to quantify the % remaining
of lipophilic component of SHS15. As lipophilic component was
found highly unstable in the rat plasma, hydrophilic component
was considered to study the pharmacokinetic disposition of SHS15
in Sprague Dawley rats.
Fig. 1 Chromatogram representing the elution pattern of hydrophilic and lipophilic components of SHS15 under reverse phase conditions in ELSD.
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The electrospray ionization of SHS15 produced the abundant molecular
ions for free PEG component (hydrophilic) at m/z 481.50, 521.50,
569.50, 613.50, 657.50, 701.50, 745.50, 789.50, 833.50, 877.50,
921.50 and 965.50 (Fig. 2C) under positive ionization conditions.
The molecular ions of free PEG component detected were sodium
adducts. A total of 12 abundant and informative oligomers were
identiﬁed. For calculating the plasma concentrations of SHS15 as a
whole the analyte peak areas of each oligomer were summed up to
develop the calibration curve. Calibration range of 0.40–185.90 mg/mL
represents total free PEG component of SHS15. In order to characterize
the pharmacokinetic differences of SHS15 oligomers, plasma concen-
trations for each oligomer were measured against identical calibration
curves that are built based on purity of each oligomer. Electrospray
ionization of telmisartan (internal standard) produced abundant proto-
nated molecules ([MH]þ) at m/z 515.20 and an intense fragment at m/z
276.10. The LC–MS/MS method was operated with the C18 column
and a 5 min generic gradient LC method was developed for the
analysis of SHS15 in rat plasma. Final mobile phase composition used
for the analysis was 0.1% formic acid in water as aqueous phase and
100% acetone as organic modiﬁer. Response saturation at higher
calibration standards was observed with the use of acetonitrile or
methanol as organic modiﬁers.
Because of the higher sensitivity of the LC–MS/MS method,
lesser plasma sample volume (50 mL) was sufﬁcient to obtain a
lower limit of quantitation (LLOQ) of 0.40 mg/mL. Even though
the calibration range of 0.40–185.90 mg/mL was higher for
analysis on mass spectrometer, analysis of plasma samples
revealed that the plasma concentrations of SHS15 were around
1–1.5 mg/mL in the initial sampling points from intravenous
route. Therefore, if these study samples have to ﬁt into the lowng/mL standard curve, very high dilution (100–1000 fold) is
required, which is practically a limitation in drug discovery.
Instead of developing a method with high sensitivity, we tried to
develop a ﬁt for purpose bioanalytical method, by (a) diluting the
precipitated samples 10 fold after precipitation, (b) using less
sensitive mass spectrometer (3200 Qtrap), and (c) injecting less
volume of sample (10 mL). No interference at the retention times
of SHS15 (1.85 min) (Fig. 3A) and telmisartan (2.51 min) (Fig.
3B) was observed in any of the lots screened as shown in
representative chromatogram of the extracted blank plasma
sample, conﬁrming the selectivity of the present method.
Representative chromatogram of SHS15 (chromatogram repre-
senting sum of peaks of all oligomers) at LLOQ is shown in
Fig. 3C. Representative chromatogram of telmisartan at 100 ng/mL
spiked concentration is shown in Fig. 3D. The LLOQ was set at
0.40 mg/mL for SHS15 using 50 mL of rat plasma. The retention
times of SHS15 and telmisartan were reproducible throughout the
experiment and no column deterioration was observed after analysis
of plasma samples.
3.4. Method validation
The developed method was validated as per the FDAs bioana-
lytical method validation guidelines [11]. Calibration curve was
linear over the concentration range of 0.40–185.90 mg/mL with
mean correlation coefﬁcient of Z0.9978. Quadratic regression
analysis with a weighting of 1/(x x) gave the optimum
accuracy of the corresponding calculated concentrations at each
level (Table 1). The low CV value for the slope indicated the
repeatability of the method (Table 1). Table 2 shows a summary
of intra- and inter-day precision and accuracy data for QC
samples containing SHS15. Both intra- and inter-assay CV
Fig. 2 (A) Remaining (%) vs time curve representing the plasma stability of hydrophilic and lipophilic components of SHS15. (B) Parent ion
(full scan) scan of mono- and diesters of 12-OH stearic acid. (C) Parent ion (full scan) scan of free PEG oligomers.
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intra- and inter-assay RE values for SHS15 were 6.75% to
5.69% at three QC levels. These results indicated that the
present method had an acceptable accuracy and precision. As
shown in Table 3, the overall extraction efﬁciency of SHS15
was 99.24%, which was consistent with a total % CV less than
0.59% at three QC concentration levels. Mean matrix factor
values of 1.00 (Table 3) at three QC levels showed that the
developed method was totally free of matrix effects for the
analysis of SHS15. Acceptable matrix factor range forqualifying the method to be free from matrix effects was
0.85–1.15. Protein precipitation was successfully applied to
the extraction of SHS15 from rat plasma. Extracted QC samples
were stable when stored at 4 1C for 24 h (autosampler stability)
prior to injection, with o8.67% (Table 3) difference from
theoretical concentration. Spiked QC samples were stable when
stored at room temperature for 8 h (bench-top stability) prior to
injection, with o6.16% (Table 3) difference from theoretical
concentration. Spiked QC samples were stable for three freeze-
thaw cycles (freeze-thaw stability) with o7.50% (Table 3)
Fig. 3 pMRM LC–MS/MS chromatograms of (A) SHS in blank rat plasma, (B) telmisartan in rat blank plasma, (C) rat plasma sample spiked
with 0.40 μg/mL of SHS15 (summed peak area of 12 PEG oligomers) (LLOQ), and (D) telmisartan spiked at 100 ng/mL concentration in rat
plasma.
Table 1 Calculated concentrations and statistical parameters of SHS15 (free PEG oligomers) calibration standards prepared in rat plasma
(n¼3).
Concentration (mg/mL) SD CV (%) Relative error (%) Accuracy (%)
Actual conc Set-1 Set-2 Set-3 Mean
0.40 0.38 0.40 0.39 0.39 0.01 3.06 2.81 97.19
0.80 0.91 0.80 1.00 0.90 0.10 11.09 13.03 113.03
4.01 3.54 3.93 4.41 3.96 0.44 11.07 1.29 98.71
20.04 20.96 19.32 19.17 19.82 0.99 5.01 1.11 98.89
57.26 54.67 62.24 53.71 56.87 4.67 8.22 0.67 99.33
104.12 114.11 105.69 104.71 108.17 5.17 4.78 3.89 103.89
148.74 144.27 140.07 161.84 148.73 11.55 7.76 0.01 99.99
167.31 164.65 168.81 158.37 163.94 5.26 3.21 2.01 97.99
185.90 179.71 184.18 166.97 176.95 8.93 5.05 4.81 95.19
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80 1C was proved for a period of 60 days witho3.26% (Table 3)
difference from theoretical concentration.3.5. Application study
3.5.1. SHS15
This method has been successfully applied to the bioanalysis of rat
plasma samples in absolute bioavailability study of SHS15.
Representative chromatograms of SHS15 from intravenous (1.00 h)
and oral (1.00 h) study samples are shown in Fig. 4A and B,
respectively. Intravenous and oral concentration/time proﬁles of
SHS15 are represented in Fig. 5A and B, respectively. As SHS15had a clear absorption and elimination phase in oral route of
administration and clear elimination phase in intravenous route of
administration, measuring plasma concentrations along with NCEs
helped to take a decision on the spiky proﬁle of NCEs. Monitoring
formulation vehicles concentrations from pharmacokinetic study
samples acted as quality control check starting from dose preparation
to bioanalysis. Intravenous and oral pharmacokinetic parameters of
SHS15 are listed in Tables 4 and 5 respectively. The mean oral
bioavailability of SHS15 was measured as 13.74% with a mean
terminal half life of 6.72 h. Mean Tmax and Cmax after oral
administration of SHS15 to Sprague Dawley rats were 0.67 h and
109.02 mg/mL, respectively. Mean residence time after intravenous
and oral administration of SHS15 to Sprague Dawley rats was 3.78
and 6.38 h, respectively.
Table 2 Precision and accuracy of SHS15 (free PEG oligomers) in quality control samples.
Type Concentration (mg/mL) Mean (mg/mL) SD CV (%) Accuracy (%) Relative error (%)
Intra-day set-1 (n¼6) LQCa 1.67 0.11 6.83 101.98 1.98
MQCb 109.22 5.95 5.45 93.25 6.75
QCc 14.98 8.89 5.93 96.04 3.96
Intra-day set-2 (n¼6) LQCa 1.73 0.08 4.84 105.69 5.69
MQCb 113.81 8.30 7.29 97.18 2.82
HQCc 150.11 9.58 6.38 96.12 3.88
Intra-day set-3 (n¼6) LQCa 1.71 0.08 4.53 104.07 4.07
MQCb 110.81 5.53 4.99 94.61 5.39
HQCc 149.00 9.66 6.48 95.41 4.59
Inter-day (n¼18) LQCa 1.70 0.03 1.79 103.91 3.91
MQCb 111.28 2.33 2.10 95.01 4.99
HQCc 149.69 0.61 0.41 95.86 4.14
aLQC¼1.64 mg/mL.
bMQC¼117.12 mg/mL.
cHQC¼156.16 mg/mL.
Table 3 Summary of validation parameters for SHS15 (free PEG oligomers) in rat plasma.
Validation parameter Mean (%) (n¼6) SD CV (%)
Extraction recovery 99.24 0.59 0.59
Matrix factor (matrix effect) 1.00 0.06 6.37
Autosampler stability 102.63 8.67 8.45
Bench-top stability 100.77 6.16 6.12
Freeze-thaw stability 100.93 7.50 7.44
Long-term stability 101.55 3.26 3.21
Fig. 4 pMRM LC–MS/MS chromatograms of (A) plasma sample obtained 1.00 h after intravenous administration of SHS15 to SD rats and (B)
plasma sample obtained 1.00 h after oral administration of SHS15 to SD rats.
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Fig. 5 Mean concentration-time proﬁle of SHS15 (free PEG oligomers) after (A) intravenous administration at 0.37 g/kg dose (free PEG
component) to SD rats and (B) oral administration at 0.92 g/kg (free PEG component) dose to SD rats.
Table 4 Pharmacokinetic parameters of SHS15 after intravenous administration at 1.00 g/kg dose in male Sprague Dawley rats (n¼3).
Subject Kel
(1/h)
T1/2
(h)
C0
(mg/
mL)
AUClast
(h mg/
mL)
AUCINF_obs
(h mg/mL)
AUC_%Extrap_obs
(%)
Vz_obs
(L/kg)
Cl_obs
(mL/
min kg)
MRTlast
(h)
RAT-1 0.10 6.92 1999.02 1615.46 1702.53 5.11 2.15 3.59 3.52
RAT-2 0.10 7.01 1148.51 1273.69 1349.79 5.64 2.75 4.53 4.06
RAT-3 0.10 6.73 1490.49 1426.95 1504.51 5.16 2.37 4.06 3.76
Mean 0.10 6.89 1546.01 1438.70 1518.94 5.30 2.42 4.06 3.78
SD 0.00 0.14 427.96 171.19 176.81 0.29 0.30 0.47 0.27
CV% 2.07 2.05 27.68 11.90 11.64 5.49 12.45 11.55 7.16
Table 5 Pharmacokinetic parameters of SHS15 after oral administration at 2.50 g/kg in male Sprague Dawley rats (n¼3).
Subject Kel
(1/h)
T1/2
(h)
Tmax
(h)
Cmax
(mg/
mL)
AUClast
(h mg/
mL)
AUCINF_obs
(h mg/mL)
AUC_%Extrap_obs
(%)
Vz_F_obs
(L/kg)
Cl_F_obs
(mL/min
kg)
MRTlast
(h)
F (%)
RAT-1 0.11 6.56 0.50 87.81 533.54 573.51 6.97 15.12 26.63 6.95 15.10
RAT-2 0.10 7.08 0.50 130.51 414.15 457.78 9.53 20.44 33.36 5.47 12.06
RAT-3 0.11 6.51 1.00 108.73 500.06 534.14 6.38 16.10 28.59 6.72 14.07
Mean 0.10 6.72 0.67 109.02 482.58 521.81 7.63 17.22 29.53 6.38 13.74
SD 0.00 0.32 0.29 21.35 61.58 58.84 1.67 2.83 3.46 0.80 1.55
CV% 4.58 4.69 43.30 19.58 12.76 11.28 21.96 16.43 11.73 12.50 11.28
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Mean intravenous and oral pharmacokinetic parameters of SHS15
oligomers are presented in Tables 6 and 7, respectively. It was
found that upon increase in molecular weight of oligomers, there
was decrease in absolute bioavailability [12,13]. This could be
attributed to decrease in permeability with increase in molecular
weight of oligomer. All the oligomers of SHS15 have clear
absorption and elimination phase in oral route of administration
and clear elimination phase in intravenous route of administration.
So for qualifying the analytical batches, any of the 12 oligomers
can be studied along with NCEs or all the oligomers can bemonitored and summed up for reﬂecting the total SHS15
pharmacokinetic proﬁle.4. Conclusion
A rapid, sensitive and reliable LC–MS/MS method for the
determination of SHS15 in rat plasma has been successfully
developed and validated using the protein precipitation extraction
method. This method demonstrated acceptable sensitivity
(LLOQ: 0.40 mg/mL), precision, accuracy, selectivity, recovery
Table 7 Mean pharmacokinetic parameters of SHS15 oligomers after oral administration of SHS15 at 2.50 g/kg in male Sprague Dawley
rats.
Oligomer
#
Kel
(1/h)
T1/2 (h) Tmax
(h)
Cmax
(mg/
mL)
AUClast
(h mg/
mL)
AUCINF_obs
(h mg/mL)
AUC_%Extrap_obs
(%)
Vz_F_obs
(L/kg)
Cl_F_obs
(mL/min
kg)
MRTlast
(h)
F (%)
1 0.12 5.88 0.50 1.92 9.08 9.56 5.12 9.25 18.09 6.47 23.30
2 0.11 6.55 0.50 4.65 20.82 22.42 7.34 11.33 19.79 6.57 19.96
3 0.10 6.76 0.83 6.72 29.56 31.98 7.64 14.66 25.06 6.34 16.69
4 0.10 6.87 0.83 12.68 54.14 58.79 7.92 17.12 28.84 6.33 14.78
5 0.10 6.80 0.67 14.29 62.95 68.56 8.27 18.82 31.88 6.33 13.17
6 0.10 6.77 0.83 14.66 58.67 63.74 8.01 20.27 34.59 6.21 11.72
7 0.10 6.95 0.83 13.27 54.09 59.10 8.63 21.76 35.99 6.37 11.62
8 0.09 7.50 0.83 10.21 41.37 45.67 9.63 30.57 46.82 6.50 8.94
9 0.09 7.55 1.00 5.69 21.91 24.33 10.10 45.57 69.45 6.42 5.99
10 0.10 7.37 1.00 2.50 10.02 11.09 9.81 58.61 91.12 6.54 4.75
11 0.08 9.06 1.00 1.64 6.97 8.15 14.39 62.21 79.70 7.17 4.58
12 0.07 9.80 1.00 0.63 2.70 3.27 17.50 72.65 85.42 7.48 4.11
Table 6 Mean pharmacokinetic parameters of SHS15 oligomers after intravenous administration of SHS15 at 1.00 g/kg in male Sprague
Dawley rats.
Oligomer
#
Kel
(1/h)
T1/2
(h)
C0
(mg/
mL)
AUClast
(h mg/
mL)
AUCINF_obs
(h mg/mL)
AUC_%Extrap_obs
(%)
Vz_obs
(L/kg)
Cl_obs
(mL/min
kg)
MRTlast
(h)
1 0.12 5.64 15.24 15.89 16.41 3.20 2.06 4.21 3.37
2 0.11 6.16 43.03 43.12 44.93 4.05 2.08 3.90 3.51
3 0.10 6.60 73.79 73.02 76.63 4.73 2.38 4.16 3.67
4 0.10 6.76 165.86 151.19 159.04 4.99 2.51 4.27 3.70
5 0.09 7.30 228.10 195.68 208.24 6.07 2.65 4.18 3.91
6 0.09 7.47 237.12 203.86 217.48 6.28 2.63 4.06 3.93
7 0.09 8.07 205.87 187.75 203.52 7.68 2.93 4.22 4.12
8 0.09 7.60 190.31 191.00 204.33 6.51 2.75 4.19 4.06
9 0.09 7.50 173.62 152.37 162.57 6.29 2.70 4.15 3.93
10 0.10 7.06 115.81 88.34 93.35 5.39 2.67 4.37 3.74
11 0.10 6.89 75.10 67.47 71.18 5.18 2.18 3.67 3.72
12 0.10 6.99 32.61 30.09 31.78 5.31 2.12 3.51 3.74
V.V. Bhaskar et al.128and stability. The validated method was successfully applied to
assay rat plasma samples and represented the plasma concentra-
tion proﬁles/pharmacokinetic parameters of SHS15 after intrave-
nous and oral administration. Pharmacokinetic parameters of
SHS15 as a whole and difference in pharmacokinetics of
oligomers were established.
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